Zhou Nana, Guo Chaoqin, Du Jingyang, Xu Qiuran, Li Juejiashan, Huang Dongsheng, Zheng Xiaoliang, Tu Linglan
School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou 310053, China.
Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Biochim Biophys Acta Mol Cell Res. 2024 Dec;1871(8):119840. doi: 10.1016/j.bbamcr.2024.119840. Epub 2024 Aug 30.
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide with a poor clinical prognosis. Protein phosphatase 1 regulatory subunit 14B (PPP1R14B) is an unidentified protein phosphatase 1 regulatory subunit that is associated with the occurrence and development of various cancers. Recently, PPP1R14B was found to contribute to paclitaxel resistance and cell progression in triple-negative breast cancer; however, the role of PPP1R14B in HCC is unknown. Here, we found that PPP1R14B was highly expressed in HCC tissues, which suggested a poor prognosis. Knockdown of PPP1R14B significantly inhibited the survival and tumorigenic ability of HCC cells, while overexpression of PPP1R14B had the opposite effects. Mechanistically, Ribosomal Protein S6 Kinase type 1(RPS6KA1) was identified as the target gene of PPP1R14B. PPP1R14B maintained the stability and phosphorylation of RPS6KA1, and positively regulated activation of the AKT/NF-κB pathway. Importantly, PPP1R14B-deficient tumor suppression could be partially restored by wild-type but not phosphorylated mutant RPS6KA1. Taken together, these findings shed light on the function and mechanism of PPP1R14B in HCC progression, indicating PPP1R14B is a promising molecular target for the treatment of HCC.
肝细胞癌(HCC)是全球最常见的癌症之一,临床预后较差。蛋白磷酸酶1调节亚基14B(PPP1R14B)是一种尚未明确的蛋白磷酸酶1调节亚基,与多种癌症的发生发展相关。最近,发现PPP1R14B在三阴性乳腺癌中导致紫杉醇耐药和细胞进展;然而,PPP1R14B在HCC中的作用尚不清楚。在此,我们发现PPP1R14B在HCC组织中高表达,提示预后不良。敲低PPP1R14B可显著抑制HCC细胞的存活和致瘤能力,而PPP1R14B过表达则产生相反的效果。机制上,核糖体蛋白S6激酶1型(RPS6KA1)被确定为PPP1R14B的靶基因。PPP1R14B维持RPS6KA1的稳定性和磷酸化,并正向调节AKT/NF-κB通路的激活。重要的是,野生型而非磷酸化突变型RPS6KA1可部分恢复PPP1R14B缺陷型的肿瘤抑制作用。综上所述,这些发现揭示了PPP1R14B在HCC进展中的功能和机制,表明PPP1R14B是治疗HCC的一个有前景的分子靶点。